SPHK1 and malignant colon neoplasm: Furthermore, pharmacological inhibition of sphingosine kinase 1 (SphK1) by N,N-dimethyl-sphingosine (DMS) or SphK1 silencing in cetuximab-resistant colon cancer cells increased their response to cetuximab [5].